📇 Rhumatologue ·

M PHILIPPE COLOMBAT

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Auteur de référence en rhumatologie
50 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (1 thèse dirigée)
Référence presse grand public
Cité 10 fois dans les médias — pédagogie reconnue

Rhumatologue

RPPS 10002021375

📊 Reconnaissance scientifique : 43/100📝 292 articles publiés🇫🇷 Publications académiques françaises (8)🎓 1 thèse dirigée

✨ Génération du profil synthétique IA en cours…

Direction de thèses

🎓 1 thèse dirigée

Etude fonctionnelle et phénotypique des effets de l'acide tout-trans rétinoi͏̈que sur les cellules CD34+ médullaires humaines

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Articles de presse (10)

Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).

"On nous appelait le service des Bisounours" : le combat humaniste contre le cancer du professeur Philippe Colombat à Tours - lanouvellerepublique.fr

📰 lanouvellerepublique.fr · 09/05/2026

<a href="https://news.google.com/rss/articles/CBMiggJBVV95cUxPMXFyUjg5aWw0SjRvTDJ0UFVHLWxKN1JqYnp4U2FONVF4UXljazRsdkI5czRjc01jYjV0THQxQUdNd29SakxuVUtncHdCQllVaHFNb3RzaDUzR2Q2WDRWNjZ3UWpLOU5JYXllNWd6WklHM3RoejF2YjBYZ0NIZzc1M0tJUjdDWEo4Y1cxOUY0ekQ5OWxuM1NUQWlOQm1oWEFlTGhKeGVBR0JVZ2VFdXoxS1Q1MHA3R3RwRl

Auditions du 5 mars 2026 - assemblee-nationale.fr

📰 assemblee-nationale.fr · 05/03/2026

<a href="https://news.google.com/rss/articles/CBMijAJBVV95cUxQWWpXMEgxSlpjSjNEQlZLVllRa2xMTmYza1NGdnpoZE5lTTlHeHQ3RWwwWGJCUkZaZS03SU5MN3pUMUJiMDlCeGd0QkIyT3pBZHRVQWNhR1hfSnEwOWgzR1BrUXdadXBveXBOdzZPZnp5NUpybnh4czR4LU1RZXpRT0FxZXZjelBXR0I5eFIzNFBGOWRBQXFGNlRzdHRTQWlWUGllMnJpb0NiZWU2c2IyZWViY2hNSThBeH

Tours : Adel Centre au soutien des enfants atteints de cancer - lanouvellerepublique.fr

📰 lanouvellerepublique.fr · 20/12/2022

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPQngxSUxQdVpGU2ExM3hDcndSa29Wb1JOM3MycnNYOFN2MEtsYnR1a0lESDlUUmpnYXdqRS1nUE9pNTBqSWlwbkNjYzJJaXQtcGFmcjRUT2FURDRGQkFORElXelQ3MWZLOVNsR3diaWdjZVVuTm9CVEJMbWNaMHdMR1FLNWwzbXJVUWhsUlhOVUtyTFc4YloyVC10TGRBNk1ia1Jr?oc=5" target="_blank">Tours :

QVT : « Tout est écrit, il faut maintenant passer à l’acte » - hospitalia.fr

📰 hospitalia.fr · 07/03/2022

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQOUF0YXFyR0JJOVhaZ0h5cDNhVjB4M29XLUhHY0JZTVNLY1VkajBYQnRoa002X2VHU0dMOFlucU85M25CYzJlbHNkRjJxX1NkZ3dvVGJSVHRVNWVnVi1idGhMa0hPYlhKZ2ZZTUdUbHFtNWVCdkgwZjJtWFQ5cTdyU2RuaDJ0LW5ZYUhIMHB1TzM5elR4LTVuSkFXV2FRZEhWRzQzTw?oc=5" target="_blank">QVT :

« A l’hôpital, les services s’en sortent mieux quand les manageurs font confiance à leurs équipes pour construire le soin » - Le Monde.fr

📰 Le Monde.fr · 28/08/2021

<a href="https://news.google.com/rss/articles/CBMimgJBVV95cUxQUjNaWDBaMnZuQnNfRFAzb3ZjNThDYVlRc3pvWnh0TjdYamtKTkJERF9nWkNUdGE4UWlGZnJwbDYyNlV5M3ExVGYxRTZaMzZzWlFkeFdiMEw4ZW0tazV1TU9xNGpXWFRXWm1HUVNvNFlreWxNa0FzRzRPM09EMlk1Q0NPTE9qLXh3SGc0OGN2LVNSSU92eDV3OUZjb0RUY3NraHN6VGhkUkhxaXNTN1V2U01aU1E3QWxxMm

La démarche participative, une réponse à la souffrance des soignants - The Conversation

📰 The Conversation · 08/01/2020

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNalNaeF9yZzFCTXVGejNBMTFPUkxHRmZnUGM3NENjSGd1bXpnd2pJU0VwQk56MlRZU0xZcXJnUnl4MmNsNHhpS0dmd1ZWRHE5Uzh2Z0RfSVUtRlg5QVJzNC1FbktBSWVHdUJrUDFuVEpnM2tEbnFkSEZaQmg3a3E4Uk1mVDkya1IycFppRUdOdGZoOU5ObGFoQVdDbF9ZQ29CUnpmNg?oc=5" target="_blank">La dé

Des soins de support à développer - lanouvellerepublique.fr

📰 lanouvellerepublique.fr · 03/10/2018

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxQMHhjdmx1Wlc0TXNKT2R1MUtIOHNkY2NjQjAtcVF1SXpLNTZweDVadHRDQkxGaXh1WUgyZ0lUMXc2d3VTaUFUMWJhNG5ubVNvTGVxNjVmUGI2STJESlRwNi1CMlZlSmNvNmdBVDg0M1prZ3NOTFY5R3NhdnJWWTNDbg?oc=5" target="_blank">Des soins de support à développer</a> <font color="#6

" Depuis dix ans, le cancer a complètement changé " - lanouvellerepublique.fr

📰 lanouvellerepublique.fr · 11/10/2015

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOa1RXQl9oMTEzN0o4WlNTZXBiZm1jem5kaW1vcWR3c0RFdzN3bnZVS2lhd3lVRmRJbXhRU2FnSFB6dENhOURWb2VKV2hmMU14d19DZUZ4MXV5MWFkbm40bUVYYXlWSkRLNE5Oellsd3lKUUh0dmNfc25nLXpjQjgzTnJGNUdnQ2pRVDMwd2x2MDhEQ08xaEQxd1Axa0JuUQ?oc=5" target="_blank">" Depuis dix

Management hospitalier : de la pratique à la bible - lanouvellerepublique.fr

📰 lanouvellerepublique.fr · 19/12/2012

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNNGlNYU1qYVNpYWdRdV9ld3VFYWkwV0VEU3ZXWXYzbEZkdHo1MzZ6SWg0SHhTNlpMY0ptVVZWa2lHZXloVjZGVm1Sbm0wNzR0VGs0eGt2djc3SVo5ZGlFbmM0TTNNcVM0R2pfb01OYWdEN2dJYU9aSVlBNjBid2NHRnVxc20wWXNrd3BTam9oSjNmV3JFSGhDRHFFanozOHRD?oc=5" target="_blank">Management

Cancéropôle Grand-Ouest : un Tourangeau à sa tête - lanouvellerepublique.fr

📰 lanouvellerepublique.fr · 01/02/2012

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQYXBUeTRtLUZROUdRTnJqVjdDaGxwMmpUWlRORlhtUEZhV3dsWW9PcHdINlo1X0t1SmZoUWZOdGZGRVdpdlBmUDZUbm51MXRZOTZSaTVtUkR1M0ltZ0JpY0ZtZUI2ai1hM05Ecm5fTjJSazhxNmQ2TjdLYmtuSC0tdGNZMUpjMVd5eEl2UzdoZTB2bThQWTl6NUxXSHdwUk0?oc=5" target="_blank">Cancéropôle

Top publications · les plus citées

Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012

📚 153 citations🎯 RCR 4.31Top 10% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Purpose[18F]Fluorodeoxyglucose positron emission tomography (PET) is widely used for the staging and restaging of patients with aggressive lymphoma, but less is known about the utility of PET in patients with follicular lymphoma (FL). In a prospective study, we evaluated the prognostic value of PET performed during treatment and at the end of treatment in 121 patients with FL treated with first-line immunochemotherapy.Patients and MethodsPatients with previously untreated high–tumor burden FL were treated with six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) plus two cycles of rituximab, without rituximab maintenance. PET was performed before treatment, after four cycles of R-CHOP (interim PET), and at the end of treatment (final PET). PET scans were centrally reviewed.ResultsThe total number of patients included was 121. Median age was 57 years. After central review, interim PET (n = 111) was negative in 76% of patients, and final PET (n = 106) was negative in 78%. With a median follow-up of 23 months, 2-year progression-free survival rates were 86% for interim PET–negative versus 61% for interim PET–positive patients (P = .0046) and 87% for final PET–negative versus 51% for final PET–positive patients (P < .001), respectively. Two-year overall survival also significantly differed according to final PET results: 100% versus 88% (P = .0128).ConclusionPET performed either after four cycles of R-CHOP or at the end of therapy was strongly predictive of outcome in this prospective study. Therapeutic intervention based on PET results during or after inductive treatment should be evaluated.

R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma

Blood · 2018

📚 143 citations🎯 RCR 5.36Top 7% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Key Points For early-stage DLBCL, R-CHOP alone is not inferior to R-CHOP followed by RT.

Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95

British journal of haematology · 2010

📚 132 citations🎯 RCR 3.19Top 15% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

SummaryPeripheral T‐Cell lymphomas (PTCL) are relatively rare diseases but appear to be highly aggressive and display worse remission and survival rates than B‐cell lymphomas. Despite unsatisfactory results with the cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) regimen, it remains the reference front‐line therapy in these diseases, but has not been challenged in phase III trials. The Groupe Ouest Est d’Etude des Leucémies et Autres Maladies du Sang (GOELAMS) devised an alternative therapeutic schedule including etoposide, ifosfamide, cisplatin alternating with doxorubicin, bleomycin, vinblastine, dacarbazine (VIP‐reinforced‐ABVD; VIP‐rABVD) and compared it to CHOP/21 as front‐line treatment in non‐cutaneous PTCL. All newly diagnosed patients were eligible. The primary objective was to improve the 2‐year event‐free survival (EFS) rate. Secondary objectives were to compare the response rate, overall survival, and toxicities as well as identify prognostic factors. Eighty‐eight patients were identified between 1996 and 2002. Both arms were well balanced for patients’ characteristics in terms of histological and clinical presentation. No significant difference was observed between the two arms in terms of 2‐year EFS. Anaplastic large cell lymphoma type and Ann Arbor stage I–II were identified as two independent favourable prognostic factors influencing survival. VIP‐rABVD was not superior to CHOP/21 in terms of EFS as first‐line treatment of PTCL, confirming that CHOP/21 remains the reference regimen in these lymphomas.

Cookies & analyse de trafic

M PHILIPPE COLOMBAT

Pourquoi vous devez consulter ce praticien

Direction de thèses

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Articles de presse (10)

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal29

Biothérapies non-anti-TNF4

Pédiatrie4

Santé mentale / fatigue3

csDMARDs2

Épidémiologie & registres2

Essai clinique2

Revue générale2

Biomarqueurs / Auto-Ac1

Case report / série1

Économie santé1

Datasets & protocoles partagés

Partager cette fiche